Search

Your search keyword '"Provenzale, Dawn"' showing total 824 results
Start Over Author "Provenzale, Dawn"
824 results on '"Provenzale, Dawn"'

151. 858 Clinical Risk Group at Baseline Is Associated With 10 Year Outcomes in a Screening Cohort-Longitudinal Analysis of the CSP 380 Cohort

Author

Lieberman, David, primary, Abbott, David H., additional, O'Leary, Meghan C., additional, Hauser, Elizabeth R., additional, Williams, Christina, additional, McNeil, Rebecca B., additional, Sullivan, Brian, additional, Musselwhite, Laura, additional, Gellad, Ziad F., additional, Weiss, David, additional, and Provenzale, Dawn, additional

Published
2016
Full Text
View/download PDF

156. Method Issues in Epidemiological Studies of Medically Unexplained Symptom-based Conditions in Veterans

Author

Coughlin, Steven S., McNeil, Rebecca B., Provenzale, Dawn T., Dursa, Erin K., and Thomas, Catherine M.

Subjects
nutritional and metabolic diseases, humanities, Article
Abstract

Symptom-based conditions such as chronic fatigue syndrome (CFS) and medically unexplained multi-symptom illness (MSI) are fairly common in the general population and are also important veteran's health concerns due to their higher frequency among U.S. veterans who served during the 1990-1991 Gulf War. CFS, MSI, and other symptom-based conditions are often associated with considerable morbidity due to fatigue, chronic pain, neurologic symptoms, and other symptoms that can impair the quality of life. This article discusses several important issues of methodology that arise in population studies of CFS and MSI. These include the exclusion criteria that have been used in population studies to define CFS-like illness and unexplained MSI, the potential for false positive and false negative assessments of illness status, the potential for sex differences, and the poorly understood natural history of these symptom-based conditions across the life span. As an empirical example of these methodology issues, we examined existing data from a 2005 follow-up survey. We found that 64.9% (762 of 1,175) of female Gulf War veterans and 53.4% (2,530 of 4,739) of male Gulf War veterans had 1 or more exclusionary medical conditions. The prevalence among veterans with one or more exclusionary medical conditions increased markedly by age among females and those with a low income.

Published
2013

157. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: A prospective cohort study

Author

Catalano, Paul J., Grambow, Steven C., Weeks, Jane C., Provenzale, Dawn, Zafar, S. Yousuf, Kolimaga, Jane T., Abbott, David H., Ayanian, John Z., Kahn, Katherine L., Ganz, Patricia A., Zullig, Leah L., West, Dee W., and Malin, Jennifer L.

Subjects
genetic structures
Abstract

Our objective was to determine how patient preferences guide the course of palliative chemotherapy for advanced colorectal cancer.

Published
2013
Full Text
View/download PDF

158. Cancer Incidence among Patients of the United States Veterans Affairs (VA) Healthcare System

Author

Zullig, Leah L., Jackson, George L., Dorn, Raye Anne, Provenzale, Dawn T., McNeil, Rebecca, Thomas, Catherine M., and Kelley, Michael J.

Subjects
Male, Lung Neoplasms, Skin Neoplasms, Incidence, Prostatic Neoplasms, Article, United States, United States Department of Veterans Affairs, Urinary Bladder Neoplasms, Neoplasms, Intestinal Neoplasms, Humans, Registries, Melanoma, Veterans
Abstract

Approximately 40,000 incident cancer cases are reported in the Veterans Affairs Central Cancer Registry (VACCR) annually (approximately 3% of U.S. cancer cases). Our objective was to provide the first comprehensive description of cancer incidence as reported in VACCR.Data were obtained from VACCR for incident cancers diagnosed in VA. Analyses focused on 2007 data. Cancer incidence among VA patients was compared to the general U.S. cancer population.In 2007, 97.5% of VA cancers were diagnosed among men. Approximately 78.5% of newly diagnosed patients were White, 19.0% Black, and 2.5% were another race. Median age at diagnosis was 66 years. The geographic distribution of cancer patients in VA aligns that of VA users. The most commonly diagnosed cancers were similar between VA and the U.S. male cancer population. The five most frequently diagnosed cancers among VA cancer patients were: prostate (31.8%), lung/bronchus (18.8%), colon/rectum (8.6%), urinary bladder (3.6%), and skin melanomas (3.4%). VA patients were diagnosed at an earlier stage of disease for the three most commonly diagnosed cancers--lung/bronchus, colon/rectum, and prostate--compared to the U.S. male cancer population.Registry data indicate that incident cancers in VA in 2007 approximately mirrored those observed among U.S. men.

Published
2012

159. Transportation — A Vehicle or Roadblock to Cancer Care for VA Patients With Colorectal Cancer?

Author

Provenzale, Dawn, Phelan, Sean, Zullig, Leah L., Van Ryn, Michelle, Griffin, Joan M., and Jackson, George L.

Subjects
food and beverages
Abstract

Patients must have transportation to the treatment site before they can access appropriate cancer care. This paper describes factors associated with patients experiencing transportation-related barriers to accessing cancer care.

Published
2012
Full Text
View/download PDF

160. Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System

Author

Provenzale, Dawn T., Thomas, Catherine M., McNeil, Rebecca, Zullig, Leah L., Jackson, George L., Kelley, Michael J., and Dorn, Raye Anne

Abstract

Approximately 40,000 incident cancer cases are reported in VA Central Cancer Registry (VACCR) annually (~3% of United States cancer cases). Our objective was to provide the first comprehensive description of cancer incidence as reported in VACCR.

Published
2012
Full Text
View/download PDF

161. Colorectal Cancer Screening, Version 1.2015

Author

Provenzale, Dawn, primary, Jasperson, Kory, additional, Ahnen, Dennis J., additional, Aslanian, Harry, additional, Bray, Travis, additional, Cannon, Jamie A., additional, David, Donald S., additional, Early, Dayna S., additional, Erwin, Deborah, additional, Ford, James M., additional, Giardiello, Francis M., additional, Gupta, Samir, additional, Halverson, Amy L., additional, Hamilton, Stanley R., additional, Hampel, Heather, additional, Ismail, Mohammad K., additional, Klapman, Jason B., additional, Larson, David W., additional, Lazenby, Audrey J., additional, Lynch, Patrick M., additional, Mayer, Robert J., additional, Ness, Reid M., additional, Rao, M. Sambasiva, additional, Regenbogen, Scott E., additional, Shike, Moshe, additional, Steinbach, Gideon, additional, Weinberg, David, additional, Dwyer, Mary A., additional, Freedman-Cass, Deborah A., additional, and Darlow, Susan, additional

Published
2015
Full Text
View/download PDF

171. Patient-Reported Quality of Supportive Care Among Patients With Colorectal Cancer in the Veterans Affairs Health Care System

Author

van Ryn, Michelle, primary, Phelan, Sean M., additional, Arora, Neeraj K., additional, Haggstrom, David A., additional, Jackson, George L., additional, Zafar, S. Yousuf, additional, Griffin, Joan M., additional, Zullig, Leah L., additional, Provenzale, Dawn, additional, Yeazel, Mark W., additional, Jindal, Rahul M., additional, and Clauser, Steven B., additional

Published
2014
Full Text
View/download PDF

173. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

Author

Zafar, S Yousuf, Zafar, S Yousuf, Malin, Jennifer L, Grambow, Steven C, Abbott, David H, Schrag, Deborah, Kolimaga, Jane T, Zullig, Leah L, Weeks, Jane C, Fouad, Mona N, Ayanian, John Z, Wallace, Robert, Kahn, Katherine L, Ganz, Patricia A, Catalano, Paul, West, Dee W, Provenzale, Dawn, Zafar, S Yousuf, Zafar, S Yousuf, Malin, Jennifer L, Grambow, Steven C, Abbott, David H, Schrag, Deborah, Kolimaga, Jane T, Zullig, Leah L, Weeks, Jane C, Fouad, Mona N, Ayanian, John Z, Wallace, Robert, Kahn, Katherine L, Ganz, Patricia A, Catalano, Paul, West, Dee W, and Provenzale, Dawn

Abstract

Background We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment. Methods We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer treated in multiple regions and health systems in the United States (US). Eligible patients were diagnosed with metastatic colorectal cancer and initiated first-line chemotherapy after US Food & Drug Administration (FDA) bevacizumab approval in February 2004. First-line bevacizumab therapy was defined as receiving bevacizumab within 8 weeks of starting chemotherapy for metastatic colorectal cancer. We evaluated factors associated with first-line bevacizumab treatment using logistic regression. Results Among 355 patients, 31% received first-line bevacizumab in the two years after FDA approval, including 26% of men, 41% of women, and 16% of those ≥ 75 years. Use rose sharply within 6 months after FDA approval, then plateaued. 20% of patients received bevacizumab in combination with irinotecan; 53% received it with oxaliplatin. Men were less likely than women to receive bevacizumab (adjusted OR 0.55; 95% CI 0.32-0.93; p = 0.026). Patients ≥ 75 years were less likely to receive bevacizumab than patients < 55 years (adjusted OR 0.13; 95% CI 0.04-0.46; p = 0.001). Conclusions One-third of eligible metastatic colorectal cancer patients received first-line bevacizumab shortly after FDA approval. Most patients did not receive bevacizumab as part of the regimen used in the pivotal study leading to FDA approval.

Published
2011

175. Colorectal Cancer Screening

Author

Burt, Randall W., primary, Cannon, Jamie A., additional, David, Donald S., additional, Early, Dayna S., additional, Ford, James M., additional, Giardiello, Francis M., additional, Halverson, Amy L., additional, Hamilton, Stanley R., additional, Hampel, Heather, additional, Ismail, Mohammad K., additional, Jasperson, Kory, additional, Klapman, Jason B., additional, Lazenby, Audrey J., additional, Lynch, Patrick M., additional, Mayer, Robert J., additional, Ness, Reid M., additional, Provenzale, Dawn, additional, Rao, M. Sambasiva, additional, Shike, Moshe, additional, Steinbach, Gideon, additional, Terdiman, Jonathan P., additional, Weinberg, David, additional, Dwyer, Mary, additional, and Freedman-Cass, Deborah, additional

Published
2013
Full Text
View/download PDF

176. Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-based Study in Utah

Author

Samadder, Jewel N., primary, Curtin, Karen, additional, Wong, Jathine, additional, Pappas, Lisa, additional, Tuohy, Therese, additional, Mineau, Geraldine, additional, Smith, Ken, additional, Pimentel, Richard, additional, Boucher, Kenneth, additional, Garrido-Laguna, Ignacio, additional, Provenzale, Dawn, additional, and Burt, Randall, additional

Published
2013
Full Text
View/download PDF

182. 8 Prevalence and Predictors of Missed or Interval Colorectal Cancer: A Population-based Study in Utah

Author

Samadder, N. Jewel, primary, Curtin, Karen, additional, Tuohy, Therese, additional, Pappas, Lisa, additional, Boucher, Kenneth M., additional, Provenzale, Dawn, additional, Rowe, Kerry, additional, Mineau, Geraldine P., additional, Smith, Ken, additional, Pimente, Richard, additional, Kirchhoff, Anne C., additional, and Burt, Randall W., additional

Published
2013
Full Text
View/download PDF

187. Barriers and Facilitators to Adoption of Genomic Services for Colorectal Care within the Veterans Health Administration.

Author

Andrews, Sara M., Sperber, Nina R., Voils, Corrine I., Green, Gregory L., Provenzale, Dawn, and Knight, Sara

Subjects
GENOMICS, HEREDITARY nonpolyposis colorectal cancer
Abstract

We examined facilitators and barriers to adoption of genomic services for colorectal care, one of the first genomic medicine applications, within the Veterans Health Administration to shed light on areas for practice change. We conducted semi-structured interviews with 58 clinicians to understand use of the following genomic services for colorectal care: family health history documentation, molecular and genetic testing, and genetic counseling. Data collection and analysis were informed by two conceptual frameworks, the Greenhalgh Diffusion of Innovation and Andersen Behavioral Model, to allow for concurrent examination of both access and innovation factors. Specialists were more likely than primary care clinicians to obtain family history to investigate hereditary colorectal cancer (CRC), but with limited detail; clinicians suggested templates to facilitate retrieval and documentation of family history according to guidelines. Clinicians identified advantage of molecular tumor analysis prior to genetic testing, but tumor testing was infrequently used due to perceived low disease burden. Support from genetic counselors was regarded as facilitative for considering hereditary basis of CRC diagnosis, but there was variability in awareness of and access to this expertise. Our data suggest the need for tools and policies to establish and disseminate well-defined processes for accessing services and adhering to guidelines. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

200. Implementation of Lung Cancer Screening in the Veterans Health Administration

Author

Kinsinger, Linda S., Anderson, Charles, Kim, Jane, Larson, Martha, Chan, Stephanie H., King, Heather A., Rice, Kathryn L., Slatore, Christopher G., Tanner, Nichole T., Pittman, Kathleen, Monte, Robert J., McNeil, Rebecca B., Grubber, Janet M., Kelley, Michael J., Provenzale, Dawn, Datta, Santanu K., Sperber, Nina S., Barnes, Lottie K., Abbott, David H., Sims, Kellie J., Whitley, Richard L., Wu, R. Ryanne, and Jackson, George L.

Abstract

IMPORTANCE: The US Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose computed tomography for current and former heavy smokers aged 55 to 80 years. There is little published experience regarding implementing this recommendation in clinical practice. OBJECTIVES: To describe organizational- and patient-level experiences with implementing an LCS program in selected Veterans Health Administration (VHA) hospitals and to estimate the number of VHA patients who may be candidates for LCS. DESIGN, SETTING, AND PARTICIPANTS: This clinical demonstration project was conducted at 8 academic VHA hospitals among 93 033 primary care patients who were assessed on screening criteria; 2106 patients underwent LCS between July 1, 2013, and June 30, 2015. INTERVENTIONS: Implementation Guide and support, full-time LCS coordinators, electronic tools, tracking database, patient education materials, and radiologic and nodule follow-up guidelines. MAIN OUTCOMES AND MEASURES: Description of implementation processes; percentages of patients who agreed to undergo LCS, had positive findings on results of low-dose computed tomographic scans (nodules to be tracked or suspicious findings), were found to have lung cancer, or had incidental findings; and estimated number of VHA patients who met the criteria for LCS. RESULTS: Of the 4246 patients who met the criteria for LCS, 2452 (57.7%) agreed to undergo screening and 2106 (2028 men and 78 women; mean [SD] age, 64.9 [5.1] years) underwent LCS. Wide variation in processes and patient experiences occurred among the 8 sites. Of the 2106 patients screened, 1257 (59.7%) had nodules; 1184 of these patients (56.2%) required tracking, 42 (2.0%) required further evaluation but the findings were not cancer, and 31 (1.5%) had lung cancer. A variety of incidental findings, such as emphysema, other pulmonary abnormalities, and coronary artery calcification, were noted on the scans of 857 patients (40.7%). CONCLUSIONS AND RELEVANCE: It is estimated that nearly 900 000 of a population of 6.7 million VHA patients met the criteria for LCS. Implementation of LCS in the VHA will likely lead to large numbers of patients eligible for LCS and will require substantial clinical effort for both patients and staff.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results